Disease on EC 3.4.24.83 - anthrax lethal factor endopeptidase
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Anemia, Sickle Cell
One-step synthesized silver micro-dendrites used as novel separation mediums and their applications in multi-DNA analysis.
Ankylosis
Generalized ankylosis, a lethal factor occurring in Friesian cattle in New Zealand. II. Its mode of inheritance.
Ankylosis
Generalized ankylosis; a lethal factor occurring in Friesian cattle in New Zealand. I. A description of the deformity and the correction of the dystocia.
Anthrax
A Bacillus anthracis strain deleted for six proteases serves as an effective host for production of recombinant proteins.
Anthrax
A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor.
Anthrax
A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.
Anthrax
A chimeric protein that functions as both an anthrax dual-target antitoxin and a trivalent vaccine.
Anthrax
A conserved motif in transmembrane helix 1 of diphtheria toxin mediates catalytic domain delivery to the cytosol.
Anthrax
A d-Amino Acid at the N-Terminus of a Protein Abrogates Its Degradation by the N-End Rule Pathway.
Anthrax
A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin action in vivo.
Anthrax
A diverse set of single-domain antibodies (VHHs) against the anthrax toxin lethal and edema factors provides a basis for construction of a bispecific agent that protects against anthrax infection.
Anthrax
A docking site in MKK4 mediates high affinity binding to JNK MAPKs and competes with similar docking sites in JNK substrates.
Anthrax
A dominant negative mutant of Bacillus anthracis protective antigen inhibits anthrax toxin action in vivo.
Anthrax
A fragment of anthrax lethal factor delivers proteins to the cytosol without requiring protective antigen.
Anthrax
A fucoidan-quaternary chitosan nanoparticle adjuvant for anthrax vaccine as an alternative to CpG oligodeoxynucleotides.
Anthrax
A Heterodimer of a VHH (Variable Domains of Camelid Heavy Chain-only) Antibody That Inhibits Anthrax Toxin Cell Binding Linked to a VHH Antibody That Blocks Oligomer Formation Is Highly Protective in an Anthrax Spore Challenge Model.
Anthrax
A new triple chimeric protein as a high immunogenic antigen against anthrax toxins: theoretical and experimental analyses.
Anthrax
A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide.
Anthrax
A non-glycosylated, plant-produced human monoclonal antibody against anthrax protective antigen protects mice and non-human primates from B. anthracis spore challenge.
Anthrax
A novel mechanism for antibody-based anthrax toxin neutralization: inhibition of prepore-to-pore conversion.
Anthrax
A Semi-Synthetic Ion Channel Platform for Detection of Phosphatase and Protease Activity.
Anthrax
A semisynthesis platform for investigating structure-function relationships in the N-terminal domain of the anthrax Lethal Factor.
Anthrax
A serological survey of Bacillus anthracis reveals widespread exposure to the pathogen in free-range and captive lions in Zimbabwe.
Anthrax
A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge.
Anthrax
A specific activation of the mitogen-activated protein kinase kinase 1 (MEK1) is required for Golgi fragmentation during mitosis.
Anthrax
A therapeutic human antibody against the domain 4 of the Bacillus anthracis protective antigen shows protective efficacy in a mouse model.
Anthrax
A two-stage, multilevel quality control system for serological assays in anthrax vaccine clinical trials.
Anthrax
Acceleration of epithelial cell syndecan-1 shedding by anthrax hemolytic virulence factors.
Anthrax
Accurate and selective quantification of anthrax protective antigen in plasma by immunocapture and isotope dilution mass spectrometry.
Anthrax
Acid-induced unfolding of the amino-terminal domains of the lethal and edema factors of anthrax toxin.
Anthrax
Acquired coagulant factor VIII deficiency induced by Bacillus anthracis lethal toxin in mice.
Anthrax
Activation of NF-?B pathway and TNF-? are involved in the cytotoxicity of anthrax lethal toxin in bovine BoMac macrophages.
Anthrax
Activation of phospholipase C and protein kinase C is required for expression of anthrax lethal toxin cytotoxicity in J774A.1 cells.
Anthrax
Activation of the NLRP1b inflammasome independently of ASC-mediated caspase-1 autoproteolysis and speck formation.
Anthrax
Alkaline earth metals are not required for the restoration of the apoform of anthrax lethal factor to its holoenzyme state.
Anthrax
An adenovirus-vectored nasal vaccine confers rapid and sustained protection against anthrax in a single-dose regimen.
Anthrax
An anthrax lethal factor mutant that is defective at causing pyroptosis retains proapoptotic activity.
Anthrax
An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin.
Anthrax
An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor.
Anthrax
An ELISA using a recombinant chimera of protective antigen and lethal factor for serodiagnosis of cutaneous anthrax in India.
Anthrax
An investigation of the pH dependence of copper-substituted anthrax lethal factor and its mechanistic implications.
Anthrax
Analysis of anti-protective antigen IgG subclass distribution in recipients of anthrax vaccine adsorbed (AVA) and patients with cutaneous and inhalation anthrax.
Anthrax
Analysis of the Errors in the Electrostatically Embedded Many-Body Expansion of the Energy and the Correlation Energy for Zn and Cd Coordination Complexes with Five and Six Ligands and Use of the Analysis to Develop a Generally Successful Fragmentation Strategy.
Anthrax
Anthrax edema factor, voltage-dependent binding to the protective antigen ion channel and comparison to LF binding.
Anthrax
Anthrax Lethal Factor (LF) Mediated Block of the Anthrax Protective Antigen (PA) Ion Channel: Effect of Ionic Strength and Voltage.
Anthrax
Anthrax Lethal Factor Activates K+ Channels To Induce IL-1{beta} Secretion in Macrophages.
Anthrax
Anthrax lethal factor as an immune target in humans and transgenic mice and the impact of HLA polymorphism on CD4+ T cell immunity.
Anthrax
Anthrax lethal factor causes proteolytic inactivation of mitogen-activated protein kinase kinase.
Anthrax
Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome.
Anthrax
Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNgamma-induced release of NO and TNFalpha.
Anthrax
Anthrax lethal factor cleaves mouse nlrp1b in both toxin-sensitive and toxin-resistant macrophages.
Anthrax
Anthrax lethal factor cleaves regulatory subunits of phosphoinositide-3 kinase to contribute to toxin lethality.
Anthrax
Anthrax lethal factor cleaves the N-terminus of MAPKKS and induces tyrosine/threonine phosphorylation of MAPKS in cultured macrophages
Anthrax
Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages.
Anthrax
Anthrax lethal factor protease inhibitors: synthesis, SAR, and structure-based 3D QSAR studies.
Anthrax
Anthrax lethal factor-cleavage products of MAPK (mitogen-activated protein kinase) kinases exhibit reduced binding to their cognate MAPKs.
Anthrax
Anthrax lethal toxin and Salmonella elicit the common cell death pathway of caspase-1-dependent pyroptosis via distinct mechanisms.
Anthrax
Anthrax lethal toxin co-complexes are stabilized by contacts between adjacent lethal factors.
Anthrax
Anthrax lethal toxin disrupts intestinal barrier function and causes systemic infections with enteric bacteria.
Anthrax
Anthrax lethal toxin disrupts the endothelial permeability barrier through blocking p38 signaling.
Anthrax
Anthrax lethal toxin down-regulates type-IIA secreted phospholipase A(2) expression through MAPK/NF-kappaB inactivation.
Anthrax
Anthrax lethal toxin downregulates claudin-5 expression in human endothelial tight junctions.
Anthrax
Anthrax lethal toxin enhances cytokine-induced VCAM-1 expression on human endothelial cells.
Anthrax
Anthrax lethal toxin enhances IkappaB kinase activation and differentially regulates pro-inflammatory genes in human endothelium.
Anthrax
Anthrax lethal toxin enhances TNF-induced endothelial VCAM-1 expression via an IFN regulatory factor-1-dependent mechanism.
Anthrax
Anthrax lethal toxin has direct and potent inhibitory effects on B cell proliferation and immunoglobulin production.
Anthrax
Anthrax lethal toxin impairs CD1d-mediated antigen presentation by targeting the extracellular signal-related kinase 1/2 mitogen-activated protein kinase pathway.
Anthrax
Anthrax lethal toxin impairs IL-8 expression in epithelial cells through inhibition of histone H3 modification.
Anthrax
Anthrax lethal toxin impairs innate immune functions of alveolar macrophages and facilitates Bacillus anthracis survival.
Anthrax
Anthrax Lethal Toxin Increases Superoxide Production in Murine Neutrophils via Differential Effects on MAPK Signaling Pathways.
Anthrax
Anthrax lethal toxin induced lysosomal membrane permeabilization and cytosolic cathepsin release is Nlrp1b/Nalp1b-dependent.
Anthrax
Anthrax lethal toxin induces acute diastolic dysfunction in rats through disruption of the phospholamban signaling network.
Anthrax
Anthrax lethal toxin induces cell death-independent permeability in zebrafish vasculature.
Anthrax
Anthrax lethal toxin induces ketotifen-sensitive intradermal vascular leakage in certain inbred mice.
Anthrax
Anthrax Lethal Toxin Inhibits Growth of and Vascular Endothelial Growth Factor Release from Endothelial Cells Expressing the Human Herpes Virus 8 Viral G Protein Coupled Receptor.
Anthrax
Anthrax lethal toxin inhibits translation of hypoxia-inducible factor 1? and causes decreased tolerance to hypoxic stress.
Anthrax
Anthrax lethal toxin kills macrophages in a strain-specific manner by apoptosis or caspase-1-mediated necrosis.
Anthrax
Anthrax lethal toxin paralyzes actin-based motility by blocking Hsp27 phosphorylation.
Anthrax
Anthrax lethal toxin promotes dephosphorylation of TTP and formation of processing bodies.
Anthrax
Anthrax lethal toxin rapidly activates caspase-1/ICE and induces extracellular release of interleukin (IL)-1beta and IL-18.
Anthrax
Anthrax lethal toxin rapidly reduces c-Jun levels by inhibiting c-Jun gene transcription and promoting c-Jun protein degradation.
Anthrax
Anthrax lethal toxin represses glucocorticoid receptor (GR) transactivation by inhibiting GR-DNA binding in vivo.
Anthrax
Anthrax lethal toxin suppresses chemokine production in human neutrophil NB-4 cells.
Anthrax
Anthrax lethal toxin suppresses high glucose induced VEGF over secretion through a post-translational mechanism.
Anthrax
Anthrax lethal toxin suppresses murine cardiomyocyte contractile function and intracellular Ca2+ handling via a NADPH oxidase-dependent mechanism.
Anthrax
Anthrax lethal toxin triggers the formation of a membrane-associated inflammasome complex in murine macrophages.
Anthrax
Anthrax lethal toxin-induced inflammasome formation and caspase-1 activation are late events dependent on ion fluxes and the proteasome.
Anthrax
Anthrax Lethal Toxin-Mediated Disruption of Endothelial VE-Cadherin Is Attenuated by Inhibition of the Rho-Associated Kinase Pathway.
Anthrax
Anthrax lethal toxin-mediated killing of human and murine dendritic cells impairs the adaptive immune response.
Anthrax
Anthrax oedema toxin induces anthrax toxin receptor expression in monocyte-derived cells.
Anthrax
Anthrax protective antigen: efficiency of translocation is independent of the number of ligands bound to the prepore.
Anthrax
Anthrax toxin as a molecular tool for stimulation of cytotoxic T lymphocytes: disulfide-linked epitopes, multiple injections, and role of CD4(+) cells.
Anthrax
Anthrax toxin blocks priming of neutrophils by lipopolysaccharide and by muramyl dipeptide.
Anthrax
Anthrax toxin complexes: heptameric protective antigen can bind lethal factor and edema factor simultaneously.
Anthrax
Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells.
Anthrax
Anthrax toxin induces hemolysis: an indirect effect through polymorphonuclear cells.
Anthrax
Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity.
Anthrax
Anthrax toxin lethal factor domain 3 is highly mobile and responsive to ligand binding.
Anthrax
Anthrax toxin protective antigen--insights into molecular switching from prepore to pore.
Anthrax
Anthrax toxin protective antigen: inhibition of channel function by chloroquine and related compounds and study of binding kinetics using the current noise analysis.
Anthrax
Anthrax toxin receptor drives protective antigen oligomerization and stabilizes the heptameric and octameric oligomer by a similar mechanism.
Anthrax
Anthrax toxin requires ZDHHC5-mediated palmitoylation of its surface-processing host enzymes.
Anthrax
Anthrax toxin translocation complex reveals insight into the lethal factor unfolding and refolding mechanism.
Anthrax
Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process.
Anthrax
Anthrax toxin triggers the activation of src-like kinases to mediate its own uptake.
Anthrax
Anthrax toxin uptake by primary immune cells as determined with a lethal factor-beta-lactamase fusion protein.
Anthrax
Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhage.
Anthrax
Anthrax toxin-mediated delivery of cholera toxin-A subunit into the cytosol of mammalian cells.
Anthrax
Anthrax toxin-neutralizing antibody reconfigures the protective antigen heptamer into a supercomplex.
Anthrax
Anthrax toxin: channel-forming activity of protective antigen in planar phospholipid bilayers.
Anthrax
Anthrax toxins cooperatively inhibit endocytic recycling by the Rab11/Sec15 exocyst.
Anthrax
Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling.
Anthrax
Anti-tumor activity of anthrax toxin variants that form a functional translocation pore by intermolecular complementation.
Anthrax
Antibacterial Properties of Visible-Light-Responsive Carbon-Containing Titanium Dioxide Photocatalytic Nanoparticles against Anthrax.
Anthrax
Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity.
Anthrax
Antibody Responses to a Spore Carbohydrate Antigen As a Marker of Non-fatal Inhalation Anthrax in Rhesus Macaques.
Anthrax
Antidotes to anthrax lethal factor intoxication. Part 1: Discovery of potent lethal factor inhibitors with in vivo efficacy.
Anthrax
Antidotes to anthrax lethal factor intoxication. Part 2: Structural modifications leading to improved in vivo efficacy.
Anthrax
Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.
Anthrax
Antigen delivered by anthrax lethal toxin induces the development of memory CD8+ T cells that can be rapidly boosted and display effector functions.
Anthrax
Antiplatelet activities of anthrax lethal toxin are associated with suppressed p42/44 and p38 mitogen-activated protein kinase pathways in the platelets.
Anthrax
Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase.
Anthrax
Arsenic trioxide and other arsenical compounds inhibit the NLRP1, NLRP3, and NAIP5/NLRC4 inflammasomes.
Anthrax
Asp 187 and Phe 190 residues in lethal factor are required for the expression of anthrax lethal toxin activity.
Anthrax
Assembly of the small outer capsid protein, Soc, on bacteriophage T4: a novel system for high density display of multiple large anthrax toxins and foreign proteins on phage capsid.
Anthrax
Asymmetric Cryo-EM Structure of Anthrax Toxin Protective Antigen Pore with Lethal Factor N-Terminal Domain.
Anthrax
Asymmetric hydrogenation of N-sulfonylated-alpha-dehydroamino acids: toward the synthesis of an anthrax lethal factor inhibitor.
Anthrax
Atomic structure of anthrax protective antigen pore elucidates toxin translocation.
Anthrax
Atomic Structures of Anthrax Prechannel Bound with Full-Length Lethal and Edema Factors.
Anthrax
Atomic structures of anthrax toxin protective antigen channels bound to partially unfolded lethal and edema factors.
Anthrax
ATP Depletion Via Mitochondrial F1F0 Complex by Lethal Factor is an Early Event in B. Anthracis-Induced Sudden Cell Death.
Anthrax
Auranofin protects against anthrax lethal toxin-induced activation of the Nlrp1b inflammasome.
Anthrax
Bacillus anthracis cell wall produces injurious inflammation but paradoxically decreases the lethality of anthrax lethal toxin in a rat model.
Anthrax
Bacillus anthracis lethal toxin disrupts TCR signaling in CD1d-restricted NKT cells leading to functional anergy.
Anthrax
Bacillus anthracis lethal toxin induces cell-type-specific cytotoxicity in human lung cell lines.
Anthrax
Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice.
Anthrax
Bacillus anthracis Lethal Toxin Represses MMTV Promoter Activity through Transcription Factors.
Anthrax
Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits.
Anthrax
Bacillus anthracis' Lethal Toxin Induces Broad Transcriptional Responses in Human Peripheral Monocytes.
Anthrax
Bacillus anthracis: a multi-faceted role for anthrax lethal toxin in thwarting host immune defenses.
Anthrax
Bidirectional effect of Wnt signaling antagonist DKK1 on the modulation of anthrax toxin uptake.
Anthrax
Binding of N-terminal fragments of anthrax edema factor (EF(N)) and lethal factor (LF(N)) to the protective antigen pore.
Anthrax
Biochemical and physiological changes induced by anthrax lethal toxin in J774 macrophage-like cells.
Anthrax
Biochip for the Detection of Bacillus anthracis Lethal Factor and Therapeutic Agents against Anthrax Toxins.
Anthrax
Biological and biochemical characterization of anthrax lethal factor, a proteolytic inhibitor of MEK signaling pathways.
Anthrax
Blocking anthrax lethal toxin at the protective antigen channel by using structure-inspired drug design.
Anthrax
BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin.
Anthrax
Bright fluorescent nucleic acid detection with CRISPR-Cas12a and poly(thymine) templated copper nanoparticles.
Anthrax
C/EBP?-Thr217 Phosphorylation Stimulates Macrophage Inflammasome Activation and Liver Injury.
Anthrax
C/EBPbeta phosphorylation rescues macrophage dysfunction and apoptosis induced by anthrax lethal toxin.
Anthrax
Calcium is required for the expression of anthrax lethal toxin activity in the macrophagelike cell line J774A.1.
Anthrax
Calpain-dependent cytoskeletal rearrangement exploited for anthrax toxin endocytosis.
Anthrax
Calyculin A sensitive protein phosphatase is required for Bacillus anthracis lethal toxin induced cytotoxicity.
Anthrax
Cathepsin B-mediated autophagy flux facilitates the anthrax toxin receptor 2-mediated delivery of anthrax lethal factor into the cytoplasm.
Anthrax
Cationic quaternized aminocalix[4]arenes: cytotoxicity, haemolytic and antibacterial activities.
Anthrax
CCT chaperonin complex is required for efficient delivery of anthrax toxin into the cytosol of host cells.
Anthrax
CD1d-dependent B-cell help by NK-like T cells leads to enhanced and sustained production of Bacillus anthracis lethal toxin-neutralizing antibodies.
Anthrax
Cellular adaptation to anthrax lethal toxin-induced mitochondrial cholesterol enrichment, hyperpolarization, and reactive oxygen species generation through downregulating MLN64 in macrophages.
Anthrax
Characterization of MPF and MAPK activities during meiotic maturation of Xenopus tropicalis oocytes.
Anthrax
Characterization of Novel Piperidine-Based Inhibitor of Cathepsin B-Dependent Bacterial Toxins and Viruses.
Anthrax
Characterization of Protein-Protein Interfaces through a Protein Contact Network Approach.
Anthrax
Characterization of the native form of anthrax lethal factor for use in the toxin neutralization assay.
Anthrax
Chemical genetic screening identifies critical pathways in anthrax lethal toxin-induced pathogenesis.
Anthrax
Chemical genetics reveals a kinase-independent role for protein kinase R in pyroptosis.
Anthrax
Chemical screening by mass spectrometry to identify inhibitors of anthrax lethal factor.
Anthrax
Chloroplast-derived anthrax and other vaccine antigens: their immunogenic and immunoprotective properties.
Anthrax
Cleavage of the JunB transcription factor by caspases generates a carboxyl-terminal fragment that inhibits activator protein-1 transcriptional activity.
Anthrax
Clindamycin Protects Nonhuman Primates Against Inhalational Anthrax But Does Not Enhance Reduction of Circulating Toxin Levels When Combined With Ciprofloxacin.
Anthrax
Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis.
Anthrax
Cloning, expression and purification of binding domains of lethal factor and protective antigen of Bacillus anthracis in Escherichia coli and evaluation of their related murine antibody.
Anthrax
Combating the threat of anthrax: a quantitative structure-activity relationship approach.
Anthrax
Combination of two candidate subunit vaccine antigens elicits protective immunity to ricin and anthrax toxin in mice.
Anthrax
Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities.
Anthrax
Comparison of MALDI-TOF-MS and HPLC-ESI-MS/MS for Endopeptidase Activity-Based Quantification of Anthrax Lethal Factor in Serum.
Anthrax
Computational insights into the interaction of the anthrax lethal factor with the N-terminal region of its substrates.
Anthrax
Consequences and utility of the zinc-dependent metalloprotease activity of anthrax lethal toxin.
Anthrax
Constitutive MEK1 Activation Rescues Anthrax Lethal Toxin Induced Vascular Effects In Vivo.
Anthrax
COPI coatomer complex proteins facilitate the translocation of anthrax lethal factor across vesicular membranes in vitro.
Anthrax
Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.
Anthrax
Critical role of the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase-3 signaling pathway in recovery from anthrax lethal toxin-induced cell cycle arrest and MEK cleavage in macrophages.
Anthrax
Cross-linked forms of the isolated N-terminal domain of the lethal factor are potent inhibitors of anthrax toxin.
Anthrax
Cross-Reactivity of Anthrax and C2 Toxin: Protective Antigen Promotes the Uptake of Botulinum C2I Toxin into Human Endothelial Cells.
Anthrax
Cross-species prediction of human survival probabilities for accelerated anthrax vaccine absorbed (AVA) regimens and the potential for vaccine and antibiotic dose sparing.
Anthrax
Cryo-electron microscopy study of bacteriophage T4 displaying anthrax toxin proteins.
Anthrax
Cryo-EM structure of the fully-loaded asymmetric anthrax lethal toxin in its heptameric pre-pore state.
Anthrax
Crystal structure of the engineered neutralizing antibody M18 complexed to domain 4 of the anthrax protective antigen.
Anthrax
Crystallization and preliminary X-ray analysis of the vWA domain of human anthrax toxin receptor 1.
Anthrax
Cutting edge: anthrax lethal toxin inhibits activation of IFN-regulatory factor 3 by lipopolysaccharide.
Anthrax
Cys-Cys Cross-Linking Shows Contact between the N-Terminus of Lethal Factor and Phe427 of the Anthrax Toxin Pore.
Anthrax
Cytosolic delivery and characterization of the TcdB glucosylating domain by using a heterologous protein fusion.
Anthrax
Cytotoxic effects of a chimeric protein consisting of tetanus toxin light chain and anthrax toxin lethal factor in non-neuronal cells.
Anthrax
Cytotoxic T-lymphocyte epitopes fused to anthrax toxin induce protective antiviral immunity.
Anthrax
Cytotoxicity of anthrax lethal factor microinjected into macrophage cells through Sendai virus envelopes.
Anthrax
Cytotoxicity of anthrax lethal toxin to human acute myeloid leukemia cells is nonapoptotic and dependent on extracellular signal-regulated kinase 1/2 activity.
Anthrax
Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.
Anthrax
Cytotoxicity of the Vibrio vulnificus MARTX toxin Effector DUF5 is linked to the C2A Subdomain.
Anthrax
Dehydroepiandrosterone and melatonin prevent Bacillus anthracis lethal toxin-induced TNF production in macrophages.
Anthrax
Delayed toxicity associated with soluble anthrax toxin receptor decoy-Ig fusion protein treatment.
Anthrax
Delayed treatment with doxycycline has limited effect on anthrax infection in BLK57/B6 mice.
Anthrax
Delayed treatment with W1-mAb, a chimpanzee-derived monoclonal antibody against protective antigen, reduces mortality from challenges with anthrax edema or lethal toxin in rats and with anthrax spores in mice*
Anthrax
Deletion mutants of protective antigen that inhibit anthrax toxin both in vitro and in vivo.
Anthrax
Delineation of interfaces on human alpha-defensins critical for human adenovirus and human papillomavirus inhibition.
Anthrax
Delivery of exogenous protein antigens to major histocompatibility complex class I pathway in cytosol.
Anthrax
Dendritic cells endocytose Bacillus anthracis spores: implications for anthrax pathogenesis.
Anthrax
Design and use of a novel substrate for simple, rapid, and specific early detection of anthrax infection.
Anthrax
Detection and quantification of anthrax lethal factor in serum by mass spectrometry.
Anthrax
Detection of anthrax toxin by an ultrasensitive immunoassay using europium nanoparticles.
Anthrax
Detection of anthrax toxin in the serum of animals infected with Bacillus anthracis by using engineered immunoassays.
Anthrax
Development of a cell-based fluorescence resonance energy transfer reporter for Bacillus anthracis lethal factor protease.
Anthrax
Development of a competitive enzyme linked immunosorbent assay to identify epitope specific antibodies in recipients of the U.S. licensed anthrax vaccine.
Anthrax
Development of a Comprehensive, Validated Pharmacophore Hypothesis for Anthrax Toxin Lethal Factor (LF) Inhibitors Using Genetic Algorithms, Pareto Scoring, and Structural Biology.
Anthrax
Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity.
Anthrax
Differentiation of human monocytic cell lines confers susceptibility to Bacillus anthracis lethal toxin.
Anthrax
Direct proteolytic cleavage of NLRP1B is necessary and sufficient for inflammasome activation by anthrax lethal factor.
Anthrax
Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin.
Anthrax
Distinct regions of NLRP1B are required to respond to anthrax lethal toxin and metabolic inhibition.
Anthrax
Diverse mechanisms for inflammasome sensing of cytosolic bacteria and bacterial virulence.
Anthrax
Dual effect of synthetic aminoglycosides: antibacterial activity against Bacillus anthracis and inhibition of anthrax lethal factor.
Anthrax
Effect of anthrax toxin's lethal factor on ion channels formed by the protective antigen.
Anthrax
Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin.
Anthrax
Effect of pH and denaturants on the fold and metal status of anthrax lethal factor.
Anthrax
Effect of pH on stability of anthrax lethal factor: correlation between denaturation and activity.
Anthrax
Effect of pH on the catalytic function and zinc content of native and immobilized anthrax lethal factor.
Anthrax
Effects of metalloprotease anthrax lethal factor on its peptide-based inhibitor R9LF-1.
Anthrax
Efficient Neutralization of Anthrax Toxin by Chimpanzee Monoclonal Antibodies against Protective Antigen.
Anthrax
Efficient production and characterization of Bacillus anthracis lethal factor and a novel inactive mutant rLFm-Y236F.
Anthrax
Electrostatic ratchet in the protective antigen channel promotes anthrax toxin translocation.
Anthrax
Electrostatically Embedded Many-Body Expansion for Neutral and Charged Metalloenzyme Model Systems.
Anthrax
Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages.
Anthrax
Erk1/2 inactivation promotes a rapid redistribution of COP1 and degradation of COP1 substrates.
Anthrax
Erythrocytic mobilization enhanced by the granulocyte colony-stimulating factor is associated with reduced anthrax-lethal-toxin-induced mortality in mice.
Anthrax
Evaluation and binding-mode prediction of thiopyrone-based inhibitors of anthrax lethal factor.
Anthrax
Evaluation of serologic tests for diagnosis of anthrax after an outbreak of cutaneous anthrax in Paraguay.
Anthrax
Evidence that translocation of anthrax toxin's lethal factor is initiated by entry of its N terminus into the protective antigen channel.
Anthrax
Examination of anthrax lethal factor inhibition by siderophores, small hydroxamates, and protamine.
Anthrax
Exceptionally Selective Substrate Targeting by the Metalloprotease Anthrax Lethal Factor.
Anthrax
Expression and purification of anthrax toxin protective antigen from Escherichia coli.
Anthrax
Expression of either lethal toxin or edema toxin by Bacillus anthracis is sufficient for virulence in a rabbit model of inhalational anthrax.
Anthrax
Expression of Nlrp1b inflammasome components in human fibroblasts confers susceptibility to anthrax lethal toxin.
Anthrax
Fluid support worsens outcome and negates the benefit of protective antigen-directed monoclonal antibody in a lethal toxin-infused rat Bacillus anthracis shock model.
Anthrax
Frontline Science: Anthrax lethal toxin-induced, NLRP1-mediated IL-1? release is a neutrophil and PAD4-dependent event.
Anthrax
Full Sequence Amino Acid Scanning of ?-Defensin RTD-1 Yields a Potent Anthrax Lethal Factor Protease Inhibitor.
Anthrax
Functional and Evolutionary Analyses Identify Proteolysis as a General Mechanism for NLRP1 Inflammasome Activation.
Anthrax
Functional characterization of protease-treated Bacillus anthracis protective antigen.
Anthrax
Functional degradation: A mechanism of NLRP1 inflammasome activation by diverse pathogen enzymes.
Anthrax
Functional determinants of human enteric ?-defensin HD5: crucial role for hydrophobicity at dimer interface.
Anthrax
Functional mapping of anthrax toxin lethal factor by in-frame insertion mutagenesis.
Anthrax
Fused polycationic peptide mediates delivery of diphtheria toxin A chain to the cytosol in the presence of anthrax protective antigen.
Anthrax
Fusion protein of Delta 27LFn and EFn has the potential as a novel anthrax toxin inhibitor.
Anthrax
Fusions of anthrax toxin lethal factor to the ADP-ribosylation domain of Pseudomonas exotoxin A are potent cytotoxins which are translocated to the cytosol of mammalian cells.
Anthrax
Fusions of anthrax toxin lethal factor with shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells.
Anthrax
Gastric pH and Toxin Factors Modulate Infectivity and Disease Progression After Gastrointestinal Exposure to Bacillus anthracis.
Anthrax
GeneChip analyses of global transcriptional responses of murine macrophages to the lethal toxin of Bacillus anthracis.
Anthrax
Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model.
Anthrax
Generation of mouse polyclonal and human monoclonal antibodies against Bacillus anthracis toxin.
Anthrax
Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity.
Anthrax
Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering.
Anthrax
GRP78(BiP) facilitates the cytosolic delivery of anthrax lethal factor (LF) in vivo and functions as an unfoldase in vitro.
Anthrax
Guanidinylated 2,5-dideoxystreptamine derivatives as anthrax lethal factor inhibitors.
Anthrax
HDAC8 Activates AKT through Upregulating PLCB1 and Suppressing DESC1 Expression in MEK1/2 Inhibition-Resistant Cells.
Anthrax
HDAC8 Prevents Anthrax Lethal Toxin-induced Cell Cycle Arrest through Silencing PTEN in Human Monocytic THP-1 Cells.
Anthrax
HDAC8-mediated epigenetic reprogramming plays a key role in resistance to anthrax lethal toxin-induced pyroptosis in macrophages.
Anthrax
Heat shock inhibits caspase-1 activity while also preventing its inflammasome-mediated activation by anthrax lethal toxin.
Anthrax
Hemodynamic effects of anthrax toxins in the rabbit model and the cardiac pathology induced by lethal toxin.
Anthrax
High metal substitution tolerance of anthrax lethal factor and characterization of its active copper-substituted analogue.
Anthrax
High throughput detection of human neutrophil peptides from serum, saliva, and tear by anthrax lethal factor-modified nanoparticles.
Anthrax
High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation.
Anthrax
High-sensitivity MALDI-TOF MS quantification of anthrax lethal toxin for diagnostics and evaluation of medical countermeasures.
Anthrax
Highly dynamic metal exchange in anthrax lethal factor involves the occupation of an inhibitory metal binding site.
Anthrax
Highly predictive support vector machine (SVM) models for anthrax toxin lethal factor (LF) inhibitors.
Anthrax
Hijacking multivesicular bodies enables long-term and exosome-mediated long-distance action of anthrax toxin.
Anthrax
HIV vaccine candidates generate in vitro T cell response to putative epitopes in Chinese-origin rhesus macaques.
Anthrax
Human alpha-defensins neutralize anthrax lethal toxin and protect against its fatal consequences.
Anthrax
Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed.
Anthrax
Human Monoclonal Antibodies against Anthrax Lethal Factor and Protective Antigen Act Independently To Protect against Bacillus anthracis Infection and Enhance Endogenous Immunity to Anthrax.
Anthrax
Humanized {theta}-Defensins (Retrocyclins) Enhance Macrophage Performance and Protect Mice from Experimental Anthrax Infections.
Anthrax
Hydrophobic residues Phe552, Phe554, Ile562, Leu566, and Ile574 are required for oligomerization of anthrax protective antigen.
Anthrax
Identification and validation of a linear protective neutralizing epitope in the ?-pore domain of alpha toxin.
Anthrax
Identification of a lead small-molecule inhibitor of anthrax lethal toxin by using fluorescence-based high-throughput screening.
Anthrax
Identification of a novel zinc metalloprotease through a global analysis of Clostridium difficile extracellular proteins.
Anthrax
Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin.
Anthrax
Identification of a Substrate-selective Exosite within the Metalloproteinase Anthrax Lethal Factor.
Anthrax
Identification of amino acid residues of anthrax protective antigen involved in binding with lethal factor.
Anthrax
Identification of exosite-targeting inhibitors of anthrax lethal factor by high-throughput screening.
Anthrax
Identification of New Dominant-Negative Mutants of Anthrax Protective Antigen Using Directed Evolution.
Anthrax
Identification of novel anthrax lethal factor inhibitors generated by combinatorial Pictet-Spengler reaction followed by screening in situ.
Anthrax
Identification of novel non-hydroxamate anthrax toxin lethal factor inhibitors by topomeric searching, docking and scoring, and in vitro screening.
Anthrax
Identification of two aberrant transcripts derived from a hybridoma with amplification of functional immunoglobulin variable genes.
Anthrax
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
Anthrax
Imaging the Cell Entry of the Anthrax Edema and Lethal toxins with Fluorescent Protein Chimeras.
Anthrax
Immune system paralysis by anthrax lethal toxin: the roles of innate and adaptive immunity.
Anthrax
Immunization by Application of DNA Vaccine onto a Skin Area Wherein the Hair Follicles Have Been Induced into Anagen-onset Stage.
Anthrax
Impaired function of the Tie-2 receptor contributes to vascular leakage and lethality in anthrax.
Anthrax
In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity.
Anthrax
In vitro binding of anthrax protective antigen on bacteriophage T4 capsid surface through Hoc-capsid interactions: a strategy for efficient display of large full-length proteins.
Anthrax
In-cell production of a genetically-encoded library based on the ?-defensin RTD-1 using a bacterial expression system.
Anthrax
Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells treated with an anthrax toxin fusion protein.
Anthrax
Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity.
Anthrax
Inflammasome Sensor NLRP1 Controls Rat Macrophage Susceptibility to Toxoplasma gondii.
Anthrax
Inflammasome sensor Nlrp1b-dependent resistance to anthrax is mediated by caspase-1, IL-1 signaling and neutrophil recruitment.
Anthrax
Influence of chemical denaturants on the activity, fold and zinc status of anthrax lethal factor.
Anthrax
Inhibition of anthrax lethal factor by curcumin and chemically modified curcumin derivatives.
Anthrax
Inhibition of anthrax toxins with a bispecific monoclonal antibody that cross reacts with edema factor as well as lethal factor of Bacillus anthracis.
Anthrax
Inhibition of bacterial carbonic anhydrases and zinc proteases: from orphan targets to innovative new antibiotic drugs.
Anthrax
Inhibition of IL-1? Expression by Anthrax Lethal Toxin is Reversed by HDAC8 Inhibition in Murine Macrophages.
Anthrax
Inhibition of interleukin 1? (IL-1?) expression by anthrax lethal toxin (LeTx) is reversed by histone deacetylase 8 (HDAC8) inhibition in murine macrophages.
Anthrax
Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo.
Anthrax
Inhibition of S. aureus alpha-hemolysin and B. anthracis lethal toxin by beta-cyclodextrin derivatives.
Anthrax
Inhibition of the adenylyl cyclase toxin, edema factor, from Bacillus anthracis by a series of 18 mono- and bis-(M)ANT-substituted nucleoside 5'-triphosphates.
Anthrax
Inhibition of the proteolytic activity of anthrax lethal factor by aminoglycosides.
Anthrax
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.
Anthrax
Innate immune response during Yersinia infection: critical modulation of cell death mechanisms through phagocyte activation.
Anthrax
Insights into the anthrax lethal factor-substrate interaction and selectivity using docking and molecular dynamics simulations.
Anthrax
Insilico studies on anthrax lethal factor inhibitors: pharmacophore modeling and virtual screening approaches towards designing of novel inhibitors for a killer.
Anthrax
Insufficient Anthrax Lethal Toxin Neutralization Is Associated with Antibody Subclass and Domain Specificity in the Plasma of Anthrax-Vaccinated Individuals.
Anthrax
Integrated microfluidic enzyme reactor mass spectrometry platform for detection of anthrax lethal factor.
Anthrax
Inter-alpha-inhibitor proteins are endogenous furin inhibitors and provide protection against experimental anthrax intoxication.
Anthrax
Interactions of anthrax lethal factor with protective antigen defined by site-directed spin labeling.
Anthrax
Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species.
Anthrax
Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin.
Anthrax
Internalization and processing of Bacillus anthracis lethal toxin by toxin-sensitive and -resistant cells.
Anthrax
Internalization of a Bacillus anthracis protective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies.
Anthrax
Intracellular calcium antagonist protects cultured peritoneal macrophages against anthrax lethal toxin-induced cytotoxicity.
Anthrax
Intramuscular delivery of adenovirus serotype 5 vector expressing humanized protective antigen induces rapid protection against anthrax that may bypass intranasally originated preexisting adenovirus immunity.
Anthrax
Invariant gly residue is important for ?-defensin folding, dimerization, and function: a case study of the human neutrophil ?-defensin HNP1.
Anthrax
Investigation of new dominant-negative inhibitors of anthrax protective antigen mutants for use in therapy and vaccination.
Anthrax
Involvement of phospholipase A2 activation in anthrax lethal toxin-induced cytotoxicity.
Anthrax
Involvement of residues 147VYYEIGK153 in binding of lethal factor to protective antigen of Bacillus anthracis.
Anthrax
Ion Conductance of the Stem of the Anthrax Toxin Channel during Lethal Factor Translocation.
Anthrax
Ion selectivity of the anthrax toxin channel and its effect on protein translocation.
Anthrax
Kif1C, a kinesin-like motor protein, mediates mouse macrophage resistance to anthrax lethal factor.
Anthrax
Killing of macrophages by anthrax lethal toxin: involvement of the N-end rule pathway.
Anthrax
Kinetics of lethal factor and poly-D-glutamic acid antigenemia during inhalation anthrax in rhesus macaques.
Anthrax
Knock-on effect of anthrax lethal toxin on macrophages potentiates cytotoxicity to endothelial cells.
Anthrax
Large-scale structural changes accompany binding of lethal factor to anthrax protective antigen: a cryo-electron microscopic study.
Anthrax
Late endosomal cholesterol accumulation leads to impaired intra-endosomal trafficking.
Anthrax
Lethal factor and anti-protective antigen IgG levels associated with inhalation anthrax, Minnesota, USA.
Anthrax
Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.
Anthrax
Lethal Factor Domain-Mediated Delivery of Nurr1 Transcription Factor Enhances Tyrosine Hydroxylase Activity and Protects from Neurotoxin-Induced Degeneration of Dopaminergic Cells.
Anthrax
Lethal factor is not required for Bacillus anthracis virulence in guinea pigs and rabbits.
Anthrax
Lethal factor toxemia and anti-protective antigen antibody activity in naturally acquired cutaneous anthrax.
Anthrax
Lethal factor unfolding is the most force-dependent step of anthrax toxin translocation.
Anthrax
Lethal factor, but not edema factor, is required to cause fatal anthrax in cynomolgus macaques after pulmonary spore challenge.
Anthrax
Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats.
Anthrax
Liposome-based nanocarriers loaded with anthrax lethal factor and armed with anti-CD19 VHH for effectively inhibiting MAPK pathway in B cells.
Anthrax
Low doses of antigen coupled to anti-CR2 mAbs induce rapid and enduring IgG immune responses in mice and in cynomolgus monkeys.
Anthrax
LRP5 and LRP6 are not required for protective antigen-mediated internalization or lethality of anthrax lethal toxin.
Anthrax
Ltx1, a mouse locus that influences the susceptibility of macrophages to cytolysis caused by intoxication with Bacillus anthracis lethal factor, maps to chromosome 11.
Anthrax
Lung epithelial injury by B. anthracis lethal toxin is caused by MKK-dependent loss of cytoskeletal integrity.
Anthrax
Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process.
Anthrax
Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis.
Anthrax
Mapping the anthrax protective antigen binding site on the lethal and edema factors.
Anthrax
Mapping the epitopes of a neutralizing antibody fragment directed against the lethal factor of Bacillus anthracis and cross-reacting with the homologous edema factor.
Anthrax
Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen.
Anthrax
Mass Spectrometric Detection of Bacterial Protein Toxins and Their Enzymatic Activity.
Anthrax
Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature.
Anthrax
Matrix metalloproteinase-activated anthrax lethal toxin inhibits endothelial invasion and neovasculature formation during in vitro morphogenesis.
Anthrax
Maturation modulates caspase-1-independent responses of dendritic cells to Anthrax lethal toxin.
Anthrax
Mechanism of Diphtheria Toxin Catalytic Domain Delivery to the Eukaryotic Cell Cytosol and the Cellular Factors that Directly Participate in the Process.
Anthrax
Mechanistic differences between in vitro assays for hydrazone-based small molecule inhibitors of anthrax lethal factor.
Anthrax
Membrane insertion of anthrax protective antigen and cytoplasmic delivery of lethal factor occur at different stages of the endocytic pathway.
Anthrax
Membrane type-1 matrix metalloproteinase (MT1-MMP) protects malignant cells from tumoricidal activity of re-engineered anthrax lethal toxin.
Anthrax
MHC class II and non-MHC class II genes differentially influence humoral immunity to Bacillus anthracis lethal factor and protective antigen.
Anthrax
Mitochondrial Impairment is a Critical Event in Anthrax Lethal Toxin-Induced Cytolysis of Murine Macrophages.
Anthrax
Mitochondrial proteins Bnip3 and Bnip3L are involved in anthrax lethal toxin-induced macrophage cell death.
Anthrax
Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma.
Anthrax
Mixed-type noncompetitive inhibition of anthrax lethal factor protease by aminoglycosides.
Anthrax
Model of the toxic complex of anthrax: responsive conformational changes in both the lethal factor and the protective antigen heptamer.
Anthrax
Modeling the effects of a Staphylococcal Enterotoxin B (SEB) on the apoptosis pathway.
Anthrax
Modified anthrax fusion proteins deliver HIV antigens through MHC Class I and II pathways.
Anthrax
Modulation of the Bacillus anthracis secretome by the immune inhibitor A1 protease.
Anthrax
Molecular analysis of the interaction of anthrax adenylyl cyclase toxin, edema factor, with 2'(3')-O-(N-(methyl)anthraniloyl)-substituted purine and pyrimidine nucleotides.
Anthrax
Monitoring endocytic trafficking of anthrax lethal factor by precise and quantitative protein labeling.
Anthrax
Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine.
Anthrax
Mouse susceptibility to anthrax lethal toxin is influenced by genetic factors in addition to those controlling macrophage sensitivity.
Anthrax
Murine innate immune response to virulent toxigenic and nontoxigenic Bacillus anthracis strains.
Anthrax
Murine macrophage transcriptional responses to Bacillus anthracis infection and intoxication.
Anthrax
Mutagenesis by retroviral insertion in chemical mutagen-generated quasi-haploid mammalian cells.
Anthrax
Mutational analysis of the enzymatic domain of Clostridium difficile toxin B reveals novel inhibitors of the wild-type toxin.
Anthrax
MyD88-dependent signaling protects against anthrax lethal toxin-induced impairment of intestinal barrier function.
Anthrax
N-fragment of edema factor as a candidate antigen for immunization against anthrax.
Anthrax
Nanopore biosensor for label-free and real-time detection of anthrax lethal factor.
Anthrax
Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli.
Anthrax
Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens.
Anthrax
Natural cutaneous anthrax infection, but not vaccination, induces a CD4(+) T cell response involving diverse cytokines.
Anthrax
Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor.
Anthrax
Neutralizing monoclonal antibody against anthrax lethal factor inhibits intoxication in a mouse model.
Anthrax
Neutrophil elastase mediates pathogenic effects of anthrax lethal toxin in the murine intestinal tract.
Anthrax
NLR proteins: integral members of innate immunity and mediators of inflammatory diseases.
Anthrax
NMR conformational properties of an Anthrax Lethal Factor domain studied by multiple amino acid-selective labeling.
Anthrax
Non-canonical effects of anthrax toxins on hem atop oiesis: implications for vaccine development.
Anthrax
Norepinephrine increases blood pressure but not survival with anthrax lethal toxin in rats.
Anthrax
Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody.
Anthrax
Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.
Anthrax
Observations on experimental anthrax; demonstration of a specific lethal factor produced in vivo by Bacillus anthracis.
Anthrax
Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells.
Anthrax
One-pot synthesis of strongly fluorescent DNA-CuInS2 quantum dots for label-free and ultrasensitive detection of anthrax lethal factor DNA.
Anthrax
One-step synthesized silver micro-dendrites used as novel separation mediums and their applications in multi-DNA analysis.
Anthrax
Participation of residue F552 in domain III of the protective antigen in the biological activity of anthrax lethal toxin.
Anthrax
Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody.
Anthrax
Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization.
Anthrax
Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs.
Anthrax
Passive vaccination with a human monoclonal antibody: Generation of antibodies and studies for efficacy in Bacillus anthracis infections.
Anthrax
Peptide- and proton-driven allosteric clamps catalyze anthrax toxin translocation across membranes.
Anthrax
Persistent inhibition of oxygen-induced retinal neovascularization by anthrax lethal toxin.
Anthrax
Phenotype based functional gene screening using retrovirus-mediated gene trapping in quasi-haploid RAW 264.7 cells.
Anthrax
Phospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF).
Anthrax
Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge.
Anthrax
Poly-gamma-d-glutamic acid and protective antigen conjugate vaccines induce functional antibodies against the protective antigen and capsule of Bacillus anthracis in guinea-pigs and rabbits.
Anthrax
Polysaccharide PCP-I isolated from Poria cocos enhances the immunogenicity and protection of an anthrax protective antigen-based vaccine.
Anthrax
Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: Implications for broad anti-tumor efficacy.
Anthrax
Predictive and fluorescent nanosensing experimental methods for evaluating anthrax protective antigen and lethal factor interactions for therapeutic applications.
Anthrax
Preventing voltage-dependent gating of anthrax toxin channels using engineered disulfides.
Anthrax
Probing the S2' Subsite of the Anthrax Toxin Lethal Factor Using Novel N-Alkylated Hydroxamates.
Anthrax
Production and purification of Bacillus anthracis protective antigen from Escherichia coli.
Anthrax
Production of biologically active Bacillus anthracis edema factor in Escherichia coli.
Anthrax
Profiling lethal factor interacting proteins from human stomach using T7 phage display screening.
Anthrax
Proteasome inhibitors prevent caspase-1-mediated disease in rodents challenged with anthrax lethal toxin.
Anthrax
Proteasomes control caspase-1 activation in anthrax lethal toxin-mediated cell killing.
Anthrax
Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine.
Anthrax
Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein.
Anthrax
Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen.
Anthrax
Protective antibody response following oral vaccination with microencapsulated Bacillus Anthracis Sterne strain 34F2 spores.
Anthrax
Protective antigen antibody augments hemodynamic support in anthrax lethal toxin shock in canines.
Anthrax
Protective antigen-binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino- or carboxy-terminus.
Anthrax
Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen.
Anthrax
Protein expression pattern of murine macrophages treated with anthrax lethal toxin.
Anthrax
Protein translocation through anthrax toxin channels formed in planar lipid bilayers.
Anthrax
Protein translocation through the anthrax toxin transmembrane pore is driven by a proton gradient.
Anthrax
Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases.
Anthrax
Proteolytic activation of receptor-bound anthrax protective antigen on macrophages promotes its internalization.
Anthrax
Proteolytic assay-based screening identifies a potent inhibitor of anthrax lethal factor.
Anthrax
Proteomic analyses of murine macrophages treated with Bacillus anthracis lethal toxin.
Anthrax
Proteomic analysis of the response of the human neutrophil-like cell line NB-4 after exposure to anthrax lethal toxin.
Anthrax
Pseudomonas exotoxin-mediated selection yields cells with altered expression of low-density lipoprotein receptor-related protein.
Anthrax
Purification and Biophysical Characterization of the Core Protease Domain of Anthrax Lethal Factor.
Anthrax
Purified Bacillus anthracis lethal toxin complex formed in vitro and during infection exhibits functional and biological activity.
Anthrax
Qualification and performance characteristics of a quantitative enzyme-linked immunosorbent assay for human lgG antibodies to anthrax lethal factor antigen.
Anthrax
Quantitative analysis of the effect of cell type and cellular differentiation on protective antigen binding to human target cells.
Anthrax
Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death.
Anthrax
Quantitative inhibitor fingerprinting of metalloproteases using small molecule microarrays.
Anthrax
Quickening the pace of anthrax research: three advances point towards possible therapies.
Anthrax
Rapid purification of recombinant anthrax-protective antigen under nondenaturing conditions.
Anthrax
Rapid vascular responses to anthrax lethal toxin in mice containing a segment of chromosome 11 from the CAST/Ei strain on a C57BL/6 genetic background.
Anthrax
Recombinant anthrax lethal toxin inhibits cell motility and invasion in breast cancer cells through the dysregulation of Rho GTPases.
Anthrax
Recombinant expression and purification of a tumor-targeted toxin in Bacillus anthracis.
Anthrax
Recombinant expression of Bacillus anthracis lethal toxin components of Indian isolate in Escherichia coli and determination of its acute toxicity level in mouse model.
Anthrax
Recombinant hepatitis B large surface antigen, successfully produced in Escherichia coli, stimulates T-cell response in mice.
Anthrax
Reduced Expression of CD45 Protein-tyrosine Phosphatase Provides Protection against Anthrax Pathogenesis.
Anthrax
Reductive methylation and mutation of an anthrax toxin fusion protein modulates its stability and cytotoxicity.
Anthrax
Repeat Dose Toxicity Study of the AV7909 Anthrax Vaccine Candidate in Juvenile Rats.
Anthrax
Residue histidine 669 is essential for the catalytic activity of Bacillus anthracis lethal factor.
Anthrax
Residues 1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides.
Anthrax
Retrocyclins kill bacilli and germinating spores of Bacillus anthracis and inactivate anthrax lethal toxin.
Anthrax
Role of a Small Molecule in the Modulation of Cell Death Signal Transduction Pathways.
Anthrax
Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model.
Anthrax
Role of residues constituting the 2beta1 strand of domain II in the biological activity of anthrax protective antigen.
Anthrax
Role of the N-terminal amino acid of Bacillus anthracis lethal factor in lethal toxin cytotoxicity and its effect on the lethal toxin neutralization assay.
Anthrax
Role of the protective antigen octamer in the molecular mechanism of anthrax lethal toxin stabilization in plasma.
Anthrax
Scalable purification of Bacillus anthracis protective antigen from Escherichia coli.
Anthrax
Search for cyclodextrin-based inhibitors of anthrax toxins: synthesis, structural features, and relative activities.
Anthrax
Secondary structure of anthrax lethal toxin proteins and their interaction with large unilamellar vesicles: a fourier-transform infrared spectroscopy approach.
Anthrax
Secondary Structure Preferences of the Anthrax Toxin Protective Antigen Translocase.
Anthrax
Secretory expression and efficient purification of recombinant anthrax toxin lethal factor with full biological activity in E. coli.
Anthrax
Selective inhibitor of endosomal trafficking pathways exploited by multiple toxins and viruses.
Anthrax
Selectively guanidinylated derivatives of neamine. Syntheses and inhibition of anthrax lethal factor protease.
Anthrax
Sensitizing anthrax lethal toxin-resistant macrophages to lethal toxin-induced killing by tumor necrosis factor-alpha.
Anthrax
Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.
Anthrax
Single, double and quadruple alanine substitutions at oligomeric interfaces identify hydrophobicity as the key determinant of human neutrophil alpha defensin HNP1 function.
Anthrax
Single-step purification of recombinant anthrax lethal factor from periplasm of Escherichia coli.
Anthrax
Site directed mutagenesis of histidine residues in anthrax toxin lethal factor binding domain reduces toxicity.
Anthrax
Small-Molecule Inhibitors of Lethal Factor Protease Activity Protect against Anthrax Infection.
Anthrax
Soluble expression and purification of the anthrax protective antigen in E. coli and identification of a novel dominant-negative mutant N435C.
Anthrax
Sometimes it takes two to tango: contributions of dimerization to functions of human ?-defensin HNP1.
Anthrax
Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization.
Anthrax
Statistical analysis, optimization, and prioritization of virtual screening parameters for zinc enzymes including the anthrax toxin lethal factor.
Anthrax
Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles.
Anthrax
Strong Mucosal and Systemic Immunities Induced by Nasal Immunization with Anthrax Protective Antigen Protein Incorporated in Liposome-Protamine-DNA Particles.
Anthrax
Structural analysis of a putative aminoglycoside N-acetyltransferase from Bacillus anthracis.
Anthrax
Structural basis for the unfolding of anthrax lethal factor by protective antigen oligomers.
Anthrax
Structural characterization of zinc-bound Zmp1, a zinc-dependent metalloprotease secreted by Clostridium difficile.
Anthrax
Structural determinants for the binding of anthrax lethal factor to oligomeric protective antigen.
Anthrax
Structural Integrity of the Alveolar-Capillary Barrier in Cynomolgus Monkeys Challenged with Fully Virulent and Toxin-Deficient Strains of Bacillus anthracis.
Anthrax
Structure of anthrax lethal toxin prepore complex suggests a pathway for efficient cell entry.
Anthrax
Structure-Activity Relationship of Semicarbazone EGA Furnishes Photoaffinity Inhibitors of Anthrax Toxin Cellular Entry.
Anthrax
Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors.
Anthrax
Study of immunization against anthrax with the purified recombinant protective antigen of Bacillus anthracis.
Anthrax
Sublethal doses of anthrax lethal toxin on the suppression of macrophage phagocytosis.
Anthrax
Sublethal Doses of Bacillus anthracis Lethal Toxin Inhibit Inflammation with Lipopolysaccharide and Escherichia coli Challenge but Have Opposite Effects on Survival.
Anthrax
Subsite specificity of anthrax lethal factor and its implications for inhibitor development.
Anthrax
Substrate recognition of anthrax lethal factor examined by combinatorial and pre-steady-state kinetic approaches.
Anthrax
Suppression of dendritic cell activation by anthrax lethal toxin and edema toxin depends on multiple factors including cell source, stimulus used, and function tested.
Anthrax
Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways.
Anthrax
Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor.
Anthrax
Susceptibility to anthrax lethal toxin is controlled by three linked quantitative trait loci.
Anthrax
Susceptibility to anthrax lethal toxin-induced rat death is controlled by a single chromosome 10 locus that includes rNlrp1.
Anthrax
Synthesis and assembly of anthrax lethal factor-cholera toxin B-subunit fusion protein in transgenic potato.
Anthrax
Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude mice.
Anthrax
Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice.
Anthrax
Targeting Cancer Gene Dependencies with Anthrax-Mediated Delivery of Peptide Nucleic Acids.
Anthrax
Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein.
Anthrax
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Anthrax
Targeting the MAP kinase pathway in astrocytoma cells using a recombinant anthrax lethal toxin as a way to inhibit cell motility and invasion.
Anthrax
Temperature-mediated recombinant anthrax protective antigen aggregate development: Implications for toxin formation and immunogenicity.
Anthrax
The 2beta(2)-2beta(3) loop of anthrax protective antigen contains a dominant neutralizing epitope.
Anthrax
The anthrax protective antigen (PA63) bound conformation of a peptide inhibitor of the binding of lethal factor to PA63: as determined by trNOESY NMR and molecular modeling.
Anthrax
The carboxyl-terminal end of protective antigen is required for receptor binding and anthrax toxin activity.
Anthrax
The channel formed in planar lipid bilayers by the protective antigen component of anthrax toxin.
Anthrax
The chymotrypsin-sensitive site, FFD315, in anthrax toxin protective antigen is required for translocation of lethal factor.
Anthrax
The CMG2 ELISA for evaluating inhibitors of the binding of anthrax toxin protective antigen to its receptor.
Anthrax
The cytotoxic activity of Bacillus anthracis lethal factor is inhibited by leukotriene A4 hydrolase and metallopeptidase inhibitors.
Anthrax
The cytotoxic effect of anthrax lethal toxin on human lung cells in vitro and the protective action of bovine antibodies to PA and LF.
Anthrax
The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection.
Anthrax
The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.
Anthrax
The effects of anthrax lethal factor on the macrophage proteome: potential activity on nitric oxide synthases.
Anthrax
The HC fragment of tetanus toxin forms stable, concentration-dependent dimers via an intermolecular disulphide bond.
Anthrax
The Heart Is an Early Target of Anthrax Lethal Toxin in Mice: A Protective Role for Neuronal Nitric Oxide Synthase (nNOS).
Anthrax
The heart is an early target of anthrax lethal toxin in mice: a protective role for neuronal nitric oxide synthase (nNOS).
Anthrax
The Impact of Protonation on Early Translocation of Anthrax Lethal Factor: Kinetics from Molecular Dynamics Simulations and Milestoning Theory.
Anthrax
The inhibition of the interaction between the anthrax toxin and its cellular receptor by an anti-receptor monoclonal antibody.
Anthrax
The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen.
Anthrax
The Major Neutralizing Antibody Responses to Recombinant Anthrax Lethal Factor and Edema Factors Are Directed to Non-Cross-Reactive Epitopes.
Anthrax
The Makes Caterpillars Floppy (MCF)-Like Domain of Vibrio vulnificus Induces Mitochondrion-Mediated Apoptosis.
Anthrax
The metalloproteolytic activity of the anthrax lethal factor is substrate-inhibited.
Anthrax
The N-end rule ubiquitin ligase UBR2 mediates NLRP1B inflammasome activation by anthrax lethal toxin.
Anthrax
The role of NF-kappaB and H3K27me3 demethylase, Jmjd3, on the anthrax lethal toxin tolerance of RAW 264.7 cells.
Anthrax
The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor.
Anthrax
The structure of Mlc titration factor A (MtfA/YeeI) reveals a prototypical zinc metallopeptidase related to anthrax lethal factor.
Anthrax
The structure of tumor endothelial marker 8 (TEM8) extracellular domain and implications for its receptor function for recognizing anthrax toxin.
Anthrax
The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: Assessment of receptor contribution.
Anthrax
Thermostabilization of protective antigen--the binding component of anthrax lethal toxin.
Anthrax
Thioamide Hydroxypyrothiones Supersede Amide Hydroxypyrothiones in Potency against Anthrax Lethal Factor.
Anthrax
Three dimensional structure of the anthrax toxin translocon-lethal factor complex by cryo-electron microscopy.
Anthrax
Toll-like receptor 4 knockout protects against anthrax lethal toxin-induced cardiac contractile dysfunction: role of autophagy.
Anthrax
Toxin Inhibition of Antimicrobial Factors Induced by Bacillus anthracis Peptidoglycan in Human Blood.
Anthrax
Toxin-neutralizing antibodies elicited by naturally acquired cutaneous anthrax are elevated following severe disease and appear to target conformational epitopes.
Anthrax
Transcriptome dysregulation by anthrax lethal toxin plays a key role in induction of human endothelial cell cytotoxicity.
Anthrax
Trapping a translocating protein within the anthrax toxin channel: implications for the secondary structure of permeating proteins.
Anthrax
Trp 346 and Leu 352 residues in protective antigen are required for the expression of anthrax lethal toxin activity.
Anthrax
Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin.
Anthrax
Tumor imaging using radiolabelled matrix metalloproteinase-activated anthrax proteins.
Anthrax
Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.
Anthrax
Ultrafast kinetic DNA hybridization assay based on the visualization of threshold turbidity.
Anthrax
Ultrasensitive detection of botulinum neurotoxins and anthrax lethal factor in biological samples by ALISSA.
Anthrax
Ultrastructural features of lymphocyte suppression induced by anthrax lethal toxin and treated with chloroquine.
Anthrax
Using common spatial distributions of atoms to relate functionally divergent influenza virus n10 and n11 protein structures to functionally characterized neuraminidase structures, toxin cell entry domains, and non-influenza virus cell entry domains.
Anthrax
Using molecular docking, 3D-QSAR, and cluster analysis for screening structurally diverse data sets of pharmacological interest.
Anthrax
Validated MALDI-TOF-MS method for anthrax lethal factor provides early diagnosis and evaluation of therapeutics.
Anthrax
Xp38gamma/SAPK3 promotes meiotic G(2)/M transition in Xenopus oocytes and activates Cdc25C.
Anthrax
Yeast-hybrid based high-throughput assay for identification of anthrax lethal factor inhibitors.
Anthrax
[Detection of the functionally active domains in the molecule of the lethal factor of the anthrax exotoxin]
Anthrax
[Expression and analysis of biological activity of the recombination anthrax edema factor]
Anthrax
[Expression, purification and characterization of the recombinant anthrax protective antigen]
Anthrax
[Monoclonal antibodies to B.anthracis protective antigen are capable to neutralize and to enhance the anthrax lethal toxin action in vitro]
Anthrax
[Screening of full human anthrax lethal factor neutralizing antibody in transgenic mice].
Anthrax
[The effect of the protective antigen of Bacillus anthracis on the formation of immunity under the action of live anthrax vaccines]
Anthrax
[Toxin-neutralizing monoclonal antibodies to the different domains of anthrax protective antigen]
Astrocytoma
Targeting the MAP kinase pathway in astrocytoma cells using a recombinant anthrax lethal toxin as a way to inhibit cell motility and invasion.
Bacterial Infections
Constitutive expression of protective antigen gene of Bacillus anthracis in Escherichia coli.
Bacterial Infections
Ligand-induced expansion of the S1' site in the anthrax toxin lethal factor.
Breast Neoplasms
Recombinant anthrax lethal toxin inhibits cell motility and invasion in breast cancer cells through the dysregulation of Rho GTPases.
Carcinogenesis
Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways.
Cholera
Synthesis and assembly of anthrax lethal factor-cholera toxin B-subunit fusion protein in transgenic potato.
coagulation factor viia deficiency
Exclusion of the first EGF domain of factor VII by a splice site mutation causes lethal factor VII deficiency.
coagulation factor viia deficiency
Factor VII gene intronic mutation in a lethal factor VII deficiency: effects on splice-site selection.
coagulation factor viia deficiency
Lethal factor VII deficiency due to novel mutations in the F7 promoter: Functional analysis reveals disruption of HNF4 binding site.
Coinfection
Circulating Lymphocyte Subsets Induce Secondary Infection in Acute Pancreatitis.
Colitis-Associated Neoplasms
Platelet Depletion/Transfusion as a Lethal Factor in a Colitis-associated Cancer Mouse Model.
Congenital Abnormalities
Generalized ankylosis; a lethal factor occurring in Friesian cattle in New Zealand. I. A description of the deformity and the correction of the dystocia.
Diphtheria
A conserved motif in transmembrane helix 1 of diphtheria toxin mediates catalytic domain delivery to the cytosol.
Diphtheria
Fusions of anthrax toxin lethal factor with shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells.
Diphtheria
IgG-Engineered Protective Antigen for Cytosolic Delivery of Proteins into Cancer Cells.
Diphtheria
Isolation of the lethal factor of diphtheria toxin by electrophoresis in starch gel.
Diphtheria
Mechanism of Diphtheria Toxin Catalytic Domain Delivery to the Eukaryotic Cell Cytosol and the Cellular Factors that Directly Participate in the Process.
Diphtheria
Peptide Probes Reveal a Hydrophobic Steric Ratchet in the Anthrax Toxin Protective Antigen Translocase.
Diphtheria
Pseudomonas exotoxin-mediated selection yields cells with altered expression of low-density lipoprotein receptor-related protein.
Diphtheria
Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death.
Diphtheria
Recombinant expression and purification of a tumor-targeted toxin in Bacillus anthracis.
Diphtheria
[Production and characteristics of monoclonal antibodies to the diphtheria toxin]
Dystocia
Generalized ankylosis; a lethal factor occurring in Friesian cattle in New Zealand. I. A description of the deformity and the correction of the dystocia.
Factor VII Deficiency
Exclusion of the first EGF domain of factor VII by a splice site mutation causes lethal factor VII deficiency.
Factor VII Deficiency
Factor VII gene intronic mutation in a lethal factor VII deficiency: effects on splice-site selection.
Factor VII Deficiency
Lethal factor VII deficiency due to novel mutations in the F7 promoter: Functional analysis reveals disruption of HNF4 binding site.
Glioma
Postoperative hydrocephalus is a high-risk lethal factor for patients with low-grade optic pathway glioma.
Hemophilia A
Acquired coagulant factor VIII deficiency induced by Bacillus anthracis lethal toxin in mice.
Hepatitis B
Recombinant hepatitis B large surface antigen, successfully produced in Escherichia coli, stimulates T-cell response in mice.
Hepatitis C
Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells treated with an anthrax toxin fusion protein.
Hepatitis E
Using common spatial distributions of atoms to relate functionally divergent influenza virus n10 and n11 protein structures to functionally characterized neuraminidase structures, toxin cell entry domains, and non-influenza virus cell entry domains.
Hydrocephalus
Postoperative hydrocephalus is a high-risk lethal factor for patients with low-grade optic pathway glioma.
Infections
An investigation of the pH dependence of copper-substituted anthrax lethal factor and its mechanistic implications.
Infections
Anthrax lethal toxin blocks MAPK kinase-dependent IL-2 production in CD4+ T cells.
Infections
Anthrax lethal toxin disrupts intestinal barrier function and causes systemic infections with enteric bacteria.
Infections
Anthrax lethal toxin has direct and potent inhibitory effects on B cell proliferation and immunoglobulin production.
Infections
Anthrax Lethal Toxin Increases Superoxide Production in Murine Neutrophils via Differential Effects on MAPK Signaling Pathways.
Infections
Anthrax lethal toxin rapidly reduces c-Jun levels by inhibiting c-Jun gene transcription and promoting c-Jun protein degradation.
Infections
Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling.
Infections
Antibody Responses to a Spore Carbohydrate Antigen As a Marker of Non-fatal Inhalation Anthrax in Rhesus Macaques.
Infections
Bacillus anthracis' Lethal Toxin Induces Broad Transcriptional Responses in Human Peripheral Monocytes.
Infections
Comparison of MALDI-TOF-MS and HPLC-ESI-MS/MS for Endopeptidase Activity-Based Quantification of Anthrax Lethal Factor in Serum.
Infections
Design and use of a novel substrate for simple, rapid, and specific early detection of anthrax infection.
Infections
Detection and quantification of anthrax lethal factor in serum by mass spectrometry.
Infections
EST-based genome-wide gene inactivation identifies ARAP3 as a host protein affecting cellular susceptibility to anthrax toxin.
Infections
Exceptionally Selective Substrate Targeting by the Metalloprotease Anthrax Lethal Factor.
Infections
Expression of either lethal toxin or edema toxin by Bacillus anthracis is sufficient for virulence in a rabbit model of inhalational anthrax.
Infections
Gastric pH and Toxin Factors Modulate Infectivity and Disease Progression After Gastrointestinal Exposure to Bacillus anthracis.
Infections
Human Monoclonal Antibodies against Anthrax Lethal Factor and Protective Antigen Act Independently To Protect against Bacillus anthracis Infection and Enhance Endogenous Immunity to Anthrax.
Infections
Inhibition of anthrax lethal factor: lability of hydroxamate as a chelating group.
Infections
Innate immune response during Yersinia infection: critical modulation of cell death mechanisms through phagocyte activation.
Infections
Insilico studies on anthrax lethal factor inhibitors: pharmacophore modeling and virtual screening approaches towards designing of novel inhibitors for a killer.
Infections
Integrated microfluidic enzyme reactor mass spectrometry platform for detection of anthrax lethal factor.
Infections
Late endosomal cholesterol accumulation leads to impaired intra-endosomal trafficking.
Infections
Murine innate immune response to virulent toxigenic and nontoxigenic Bacillus anthracis strains.
Infections
Non-canonical effects of anthrax toxins on hem atop oiesis: implications for vaccine development.
Infections
Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization.
Infections
Purified Bacillus anthracis lethal toxin complex formed in vitro and during infection exhibits functional and biological activity.
Infections
Rapid vascular responses to anthrax lethal toxin in mice containing a segment of chromosome 11 from the CAST/Ei strain on a C57BL/6 genetic background.
Infections
Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model.
Infections
Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.
Infections
Small Molecule Inhibitors of Bacillus anthracis Protective Antigen Proteolytic Activation and Oligomerization.
Infections
Small-Molecule Inhibitors of Lethal Factor Protease Activity Protect against Anthrax Infection.
Infections
Subsite specificity of anthrax lethal factor and its implications for inhibitor development.
Infections
Susceptibility to anthrax lethal toxin is controlled by three linked quantitative trait loci.
Infections
The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection.
Infections
The role of extracellular products of Pseudomonas aeruginosa in the pathogenesis of infection; an experimental study employing intraperitoneal diffusion chambers.
Influenza, Human
Role of furin in delivery of a CTL epitope of an anthrax toxin-fusion protein.
Leukemia, Myeloid, Acute
Cytotoxicity of anthrax lethal toxin to human acute myeloid leukemia cells is nonapoptotic and dependent on extracellular signal-regulated kinase 1/2 activity.
Leukemia, Myeloid, Acute
Phospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF).
Lymphoma
Cleavage of the JunB transcription factor by caspases generates a carboxyl-terminal fragment that inhibits activator protein-1 transcriptional activity.
Lymphoma, Large-Cell, Anaplastic
Cleavage of the JunB transcription factor by caspases generates a carboxyl-terminal fragment that inhibits activator protein-1 transcriptional activity.
Mediastinitis
Transesophageal irrigation for the treatment of mediastinitis produced by esophageal rupture.
Melanoma
Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase.
Melanoma
BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin.
Melanoma
Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities.
Melanoma
Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.
Melanoma
Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature.
Melanoma
Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice.
Melanoma
The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: Assessment of receptor contribution.
Meningitis
Vector-mediated selective expression of lethal factor, a toxic element of Bacillus anthracis, damages A549 cells via inhibition of MAPK and AKT pathways.
Myocardial Infarction
Physical inactivity as a lethal factor in myocardial infarction among men.
Neoplasm Metastasis
Chamaejasmenin B, a novel candidate, inhibits breast tumor metastasis by rebalancing TGF-beta paradox.
Neoplasm Metastasis
Exploration of the effect and mechanism of activating blood circulation and stasis-removing therapy on tumor metastasis.
Neoplasms
Anthrax lethal factor causes proteolytic inactivation of mitogen-activated protein kinase kinase.
Neoplasms
Anthrax lethal toxin enhances cytokine-induced VCAM-1 expression on human endothelial cells.
Neoplasms
Anthrax lethal toxin enhances IkappaB kinase activation and differentially regulates pro-inflammatory genes in human endothelium.
Neoplasms
Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities.
Neoplasms
Exploration of the effect and mechanism of activating blood circulation and stasis-removing therapy on tumor metastasis.
Neoplasms
HDAC8 Activates AKT through Upregulating PLCB1 and Suppressing DESC1 Expression in MEK1/2 Inhibition-Resistant Cells.
Neoplasms
Identification of a six lncRNAs signature as novel diagnostic biomarkers for cervical cancer.
Neoplasms
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.
Neoplasms
Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature.
Neoplasms
Pattern of tumor cell spread in tissues and organs as a lethal factor in tumor-bearing animals.
Neoplasms
Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: Implications for broad anti-tumor efficacy.
Neoplasms
Production of recombinant lethal factor of Bacillus anthracis in Bacillus subtilis.
Neoplasms
Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways.
Neoplasms
Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude mice.
Neoplasms
Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice.
Neoplasms
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Neoplasms
Tumor imaging using radiolabelled matrix metalloproteinase-activated anthrax proteins.
Neoplasms
Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.
Neuroblastoma
Burkholderia Lethal Factor 1, a Novel Anti-Cancer Toxin, Demonstrates Selective Cytotoxicity in MYCN-Amplified Neuroblastoma Cells.
Otorhinolaryngologic Diseases
[Suffocation, an important lethal factor for otorhinolaryngological disease]
Paralysis
Immune system paralysis by anthrax lethal toxin: the roles of innate and adaptive immunity.
Pseudomonas Infections
The role of extracellular products of Pseudomonas aeruginosa in the pathogenesis of infection; an experimental study employing intraperitoneal diffusion chambers.
Retinal Neovascularization
Persistent inhibition of oxygen-induced retinal neovascularization by anthrax lethal toxin.
Salmonella Infections
Anthrax lethal toxin and Salmonella elicit the common cell death pathway of caspase-1-dependent pyroptosis via distinct mechanisms.
Scoliosis
Aetiology and pathogenesis of congenital torticollis and head scoliosis in the equine foetus.
Sepsis
Paeonol Inhibits Lipopolysaccharide-Induced HMGB1 Translocation from the Nucleus to the Cytoplasm in RAW264.7 Cells.
Sepsis
Vector-mediated selective expression of lethal factor, a toxic element of Bacillus anthracis, damages A549 cells via inhibition of MAPK and AKT pathways.
Shock, Septic
Critical role of the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase-3 signaling pathway in recovery from anthrax lethal toxin-induced cell cycle arrest and MEK cleavage in macrophages.
Shock, Septic
The role of NF-kappaB and H3K27me3 demethylase, Jmjd3, on the anthrax lethal toxin tolerance of RAW 264.7 cells.
Tetanus
Cytotoxic effects of a chimeric protein consisting of tetanus toxin light chain and anthrax toxin lethal factor in non-neuronal cells.
Tetanus
Inhibition of bacterial carbonic anhydrases and zinc proteases: from orphan targets to innovative new antibiotic drugs.
Tetanus
Using common spatial distributions of atoms to relate functionally divergent influenza virus n10 and n11 protein structures to functionally characterized neuraminidase structures, toxin cell entry domains, and non-influenza virus cell entry domains.
Thyroid Carcinoma, Anaplastic
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.
Thyroid Neoplasms
[Primary hyperparathyroidism: problems on surgical indication and procedure]
Toxemia
Highly predictive support vector machine (SVM) models for anthrax toxin lethal factor (LF) inhibitors.
Toxemia
Lethal factor toxemia and anti-protective antigen antibody activity in naturally acquired cutaneous anthrax.
Toxemia
Vector-mediated selective expression of lethal factor, a toxic element of Bacillus anthracis, damages A549 cells via inhibition of MAPK and AKT pathways.
Tuberculosis
Evaluation of the ability of N-terminal fragment of lethal factor of Bacillus anthracis for delivery of Mycobacterium T cell antigen ESAT-6 into cytosol of antigen presenting cells to elicit effective cytotoxic T lymphocyte response.
Uterine Cervical Neoplasms
Identification of a six lncRNAs signature as novel diagnostic biomarkers for cervical cancer.
Vasculitis
Anthrax lethal toxin enhances TNF-induced endothelial VCAM-1 expression via an IFN regulatory factor-1-dependent mechanism.
Vesicular Stomatitis
Late endosomal cholesterol accumulation leads to impaired intra-endosomal trafficking.
Whooping Cough
Effect of hyperreactivity to endotoxin on the toxicity of pertussis vaccine and pertussis toxin in mice.
html completed